Items where Author is "Yamout, B."

Article

(2025) First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. Neurotherapeutics. p. 12. ISSN 1933-7213

(2025) Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study. Journal of neurology, neurosurgery, and psychiatry. pp. 361-369. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA neurology. ISSN 2168-6157 (Electronic) 2168-6149 (Print) 2168-6149 (Linking)

(2024) Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation. ISSN 23327812 (ISSN)

(2024) Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study. Multiple Sclerosis and Related Disorders. p. 9. ISSN 2211-0348

(2024) Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study. Journal of Neurology Neurosurgery and Psychiatry. p. 9. ISSN 0022-3050

(2023) Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 707-717. ISSN 0022-3050

(2023) Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 875-883. ISSN 1352-4585

(2023) Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. Journal of Neurology Neurosurgery and Psychiatry. pp. 1004-1011. ISSN 0022-3050

(2023) External validation of a clinical prediction model in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). pp. 261-269. ISSN 1477-0970 (Electronic) 1352-4585 (Linking)

(2023) Predictors of treatment switching in the Big Multiple Sclerosis Data Network. Frontiers in Neurology. p. 10. ISSN 1664-2295

(2023) Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. pp. 1014-1024. ISSN 1351-5101

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. pp. 2321-2334. ISSN 1351-5101 1468-1331 J9 - EUR J NEUROL

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology. pp. 2321-2334. ISSN 13515101 (ISSN)

(2022) Description of Multiple Sclerosis cohorts from the Middle East between 2009 and 2019. Multiple Sclerosis Journal. pp. 17-18. ISSN 1352-4585

(2022) Early non-disabling relapses are associated with a higher risk of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 947-950. ISSN 1352-4585

(2022) Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC MEDICAL RESEARCH METHODOLOGY. ISSN 1471-2288 J9 - BMC MED RES METHODOL

(2022) Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. Bmc Medical Research Methodology. p. 14.

(2022) The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Journal. pp. 967-970. ISSN 1352-4585

(2021) Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018. CNS Drugs. ISSN 1172-7047

(2021) The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. Mult Scler Relat Disord. p. 103012. ISSN 2211-0348

(2019) Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. Jama-Journal of the American Medical Association. pp. 175-187. ISSN 0098-7484

(2019) Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. pp. 458-468. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2018) Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis. Multiple Sclerosis Journal. pp. 135-137. ISSN 1352-4585